MicuRx is discovering and developing novel antibiotics to combat infections due to resistant bacteria. Positioned to capture the benefits of United States research and development expertise together with the high quality, cost-efficient discovery, preclinical and development infrastructure in China, the company has built a pipeline of discovery and development programs targeting Gram-positive and Gram-negative pathogens. The company has research and development facilities outside San Francisco, CA in the United States and in Shanghai, China.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/22/13 | $25,000,000 | Series B |
BVCF Morningside Group | undisclosed |
| 09/27/16 | $55,000,000 | Series C |
3E Bioventures Delian Capital GP Healthcare Capital GP TMT Capital | undisclosed |
